Agilux News
Agilux Laboratories Announces the Launch of GLP LC/MS/MS Bioanalytical Services
Expanded GLP bioanalytical testing services makes Agilux the largest bioanalytical CRO in New England.
Worcester, MA (PRWEB) January 25, 2010 -- Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides bioanalytical and in vitro ADMET services for the biotechnology and pharmaceutical industries, has launched GLP compliant LC/MS/MS bioanalytical services supporting nonclinical and clinical studies.
Founded in 2007, Agilux has grown into the largest bioanalytical contract laboratory in New England by focusing on high quality, rapid turnaround services for discovery support. Agilux can now deliver the same high quality, rapid turnaround services to support GLP compliant nonclinical and clinical studies.
The "green field" start of the GLP LC/MS/MS bioanalytical service has allowed Agilux to incorporate the very latest technology with many novel, innovative approaches. The management team's extensive knowledge and experience in the GLP bioanalytical environment result in novel, efficient processes that are fully compliant with the latest regulations. With renowned customer service, Agilux is focused on delivering "Better Data Faster"
"At Agilux, we have challenged ourselves to innovate to the advantage of our clients. Our highly successful Discovery 2.0 has demonstrated that there was room to innovate in the discovery bioanalytical services space. In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery, without compromising outstanding compliance and customer service" said Jim Jersey, president and CEO at Agilux.
About Agilux Laboratories, Inc.
Agilux Laboratories, Inc. is a contract research organization (CRO) focused on bioanalytical and PK/PD testing services for the biotech and pharmaceutical industries. Leveraging industry and contract research experience of its management team, the company delivers high quality bioanlaytical chemistry and PK/PD data more rapidly. Agilux helps clients make better decisions during drug discovery and development by providing quality data earlier in the research process by using technologies and systems that increase turnaround speed well beyond industry standards. Founded in 2007 by industry veterans Jim Jersey, Steve Guyan and Peter Glick, Agilux is headquartered in Worcester, MA, and is funded by private equity firm Ampersand Ventures. For more information, call 508-753-5000. Online at www.agiluxlabs.com.
Contact:
Steve Guyan, MS
Vice President Sales and Marketing
Ph: 508-753-5000
Fx: 508-630-1679
Info@agiluxlabs.com
